SCHEMBL15207719

SCHEMBL15207719

COc1ccc(Nc2nc3c(-c4cncc(C#N)c4)nccn3n2)cc1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 4/20 0.47
CSNK2A1 P68400 1/20 0.42
PRKCQ Q04759 1/20 0.41
TP53 P04637 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
PLK1 P53350 2/20 0.40
SYK P43405 6/20 0.40
CD63 P08962 2/20 0.40
AURKA O14965 1/20 0.39
JAK2 O60674 1/20 0.39
KIT P10721 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.39
PTK2 Q05397 1/20 0.39
CDK4 P11802 1/20 0.39
CCND1 P24385 1/20 0.39
CCND2 P30279 1/20 0.39
CCND3 P30281 1/20 0.39
EIF2AK4 Q9P2K8 1/20 0.39
PAK1 Q13153 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15208232 0.92 MAPT (0.41) FLT3PRKCQTP53GAAMAPT
SCHEMBL15207974 0.89 JAK2 (0.46) GAAMAPTAURKAJAK2PTK2
SCHEMBL15208233 0.86 NUAK1 (0.39) SYKJAK2PTK2EIF2AK4PAK1
SCHEMBL15208269 0.86 TP53 (0.46) FLT3TP53GAAMAPTPLK1
SCHEMBL21816 0.85 CHEK1 (0.49) FLT3PRKCQTP53GAAMAPT
SCHEMBL30790 0.84 JAK2 (0.39) MAPTPLK1SYKJAK2PTK2
SCHEMBL15207711 0.84 PIK3CA (0.45) FLT3CSNK2A1PRKCQTP53GAA
SCHEMBL15207273 0.84 AURKA (0.40) PLK1SYKAURKAJAK2PTK2
SCHEMBL15207388 0.83 JAK2 (0.45) FLT3TP53GAAMAPTSYK
SCHEMBL15207185 0.82 SYK (0.37) SYKJAK2PTK2EIF2AK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609098-B1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-07-13 EP disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES SYK, IRAK1, ZAP70 FLT3 16/4885CSNK2A1 287/4885PRKCQ 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.